Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,206,842 papers from all fields of science
Search
Sign In
Create Free Account
Selexid
Known as:
Leo Brand of Pivmecillinam Hydrochloride
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Amdinocillin
Amdinocillin Pivoxil
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1991
1991
[Let Selexid regain its role as a drug of first choice in lower urinary tract infections].
S. Ferry
Läkartidningen
1991
Corpus ID: 27249491
Review
1990
Review
1990
[Pivampicillin (Pondocillin) and pivmecillinam (Selexid) can result in carnitine deficiency].
T. Bøhmer
,
L. Endresen
Tidsskrift for Den Norske Laegeforening
1990
Corpus ID: 40121622
1989
1989
[Pondocillin, Selexid and carnitine].
T. Midtvedt
Tidsskrift for Den Norske Laegeforening
1989
Corpus ID: 20903745
1988
1988
[Ulcerative esophagitis after ingestion of Selexid].
A. Matteo
,
B. Eyssautier
,
F. Rodor
,
A. Gérolami
Gastroentérologie Clinique et Biologique
1988
Corpus ID: 39407875
1981
1981
[Pivmecillinam (Selexid) in acute cystitis. A comparative study of 3- and 7-day treatments].
P. H. Hansen
,
K. Kristensen
,
H. A. Lenler-Eriksen
,
J. Pagh
,
J. Ostergård
Ugeskrift for læger
1981
Corpus ID: 19508108
1978
1978
Pivmecillinam (selexid)
Drug and therapeutics bulletin
1978
Corpus ID: 30369452
Mecillinam and pivmecillinam are the first of a new group of penicillins, the amidino penicillins, which differ from other…
Expand
1978
1978
[Pivmecillinam (Selexid)].
G. Jensen
Ugeskrift for læger
1978
Corpus ID: 39810635
1978
1978
[Drug information: penicillin preparations. Therapeutic main group: antibiotics. Pivmecillinam (Selexid)].
Lumholtz Ib
Sygeplejersken: tidsskrift for sygeplejersker
1978
Corpus ID: 77585649
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE